查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840598

抗病毒治療市場依疾病類型、藥物類別、給藥途徑、通路和治療類型分類－2025-2032年全球預測

Antiviral Therapeutics Market by Disease Type, Drug Class, Route Of Administration, Distribution Channel, Therapy Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗病毒治療市場規模將達到 1,570.2 億美元，複合年成長率為 8.45%。

主要市場統計數據
基準年 2024 820.1億美元
預計年份：2025年 888.9億美元
預測年份：2032年 1570.2億美元
複合年成長率 (%) 8.45%

為決策者提供最新的抗病毒治療領域全面說明，整合科學進展、監管現狀和商業策略。

抗病毒治療領域正處於科學發現加速發展、公共衛生期望不斷變化以及競爭日益激烈的交匯點。近期趨勢表明，新型療法和給藥技術正從概念驗證邁向臨床階段，這為研發者、生產者和支付者創造了一個更複雜但也充滿機會的環境。如今，相關人員必須權衡治療方法創新與成本壓力、供應鏈脆弱性以及全球主要司法管轄區不斷變化的監管標準之間的關係。

隨著病原體頻譜的擴大和應對疫情的重要性日益凸顯，企業必須重新調整策略重點。對頻譜平台、宿主標靶療法和適應性生產的投資正日益增加。同時，支付者和採購機構也越來越重視臨床價值和真實世界療效，促使申辦者設計超越關鍵性臨床試驗的證據產生策略。因此，兼具科學嚴謹性、商業性遠見和營運韌性的領導者將引領抗病毒療法研發和應用的下一階段。

平台技術、監管改革和生產靈活性的整合如何從根本上改變抗病毒藥物的發現、開發和遞送

一系列變革性變化正在重塑抗病毒藥物的發現、開發和遞送方式。在疫情期間展現出良好適應性的平台技術，如今正被重新應用於更廣泛的病毒，從而加快先導化合物的篩選速度，並最佳化藥物開發流程。同時，日趨成熟的單株抗體工程技術和宿主定向療法的改進，也為傳統小分子抑制劑以外的治療選擇提供了更多可能。

數位化能力和人工智慧正在加速標靶發現並最佳化候選藥物篩選，而模組化和一次性生產解決方案則縮短了前置作業時間並提高了地域靈活性。這些科學和營運方面的變革與監管創新相輔相成，快速核准途徑和適應性測試設計促進了對未滿足醫療需求高的適應症的有條件准入。總而言之，這些變革共同描繪出一幅技術融合、監管靈活性和生產適應性將決定商業性成敗的格局。

評估近期美國關稅措施對抗病毒藥物供應鏈、採購和生產決策的累積營運和策略影響

2025年實施的政策變革和貿易措施為全球抗病毒藥物供應鏈和籌資策略引入了新的變數。影響關鍵原料和成品藥的關稅調整增加了跨境採購的成本，促使企業重新評估其供應商網路和庫存策略。為此，許多企業正在加快降低單一來源風險的步伐，包括本地化生產、擴大與製造外包的合作以及實現原料藥供應商多元化。

關稅不僅影響直接成本，也影響長期的策略選擇。贊助商和製造商正在重新評估新設施的位置，將關稅風險與勞動力、人才供應和監管合規性等因素納入考量。醫院、零售藥局和專科診所的採購機構正在調整合約方式，在供應保證和價格上漲機制方面提供更大的靈活性。貿易措施的累積影響凸顯了建立具有韌性的多層次供應策略的必要性，這些策略既能確保醫療服務的連續性，又能維持商業性可行性。

將疾病標靶、藥物類別、給藥途徑、分銷管道和治療目的與臨床和商業性決策聯繫起來的策略性細分洞察

主導細分市場的分析揭示了不同治療標靶和治療方式的差異化動態，從而為產品組合和商業化選擇提供基礎。急性呼吸道病毒感染需要快速起效和便捷給藥，而慢性感染疾病（如C型肝炎和愛滋病）則更注重持續性病毒抑制、依從性支持和抗藥性管理。巨細胞病毒和呼吸道融合細胞病毒等新發和再發病毒需要專門的臨床開發方法，並且通常受益於標靶生技藥品和預防策略。

不同藥物類別的差異會影響研發週期和上市推廣。小分子聚合酵素和蛋白酶抑制劑具有口服給藥和成熟生產流程的優勢，而單株抗體和干擾素通常需要注射劑型和複雜的生技藥品生產過程。融合酶和整合酶抑制劑，以及核苷類和非核苷類逆轉錄酶抑制劑，各自具有不同的抗藥性譜和聯合治療方案。口服製劑便於透過門診和零售藥局進行分銷，而注射劑通常需要醫院或專科診所的參與，吸入和局部用藥則適用於特定的呼吸系統和局部適應症。給藥途徑直接影響健保報銷管道和病人偏好。

分銷通路策略必須與產品特性和醫療保健系統能力相符。醫院藥局和專科診所在腸外生技藥品和需要監測的複雜療法方面發揮關鍵作用，而零售藥局和線上藥局則擴大了口服抗病毒藥物和預防性藥物的可及性。最後，治療目的（預防或治療）會影響臨床試驗設計、標籤細微差別和上市後證據的產生。預防性藥物通常著重於人群層面的療效和長期安全性，而治療性藥物則優先考慮即時臨床終點和抗藥性監測。整合這些細分市場有助於實現有針對性的臨床開發、量身定做的上市計劃和最佳的商業部署。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和市場准入需求影響著開發、製造和商業化選擇。

區域差異造就了截然不同的營運和法規環境，進而影響研發管線的優先排序和市場進入策略。美洲擁有完善的臨床試驗基礎設施、大量的公共和私人研發投資，以及複雜的報銷體系，這些都要求以實證醫學為基礎，證明其療效和價值優於現有標準療法。該地區的監管管道也為優先療法提供了早期准入機制，但相關人員必須應對價格審查和支付方主導的使用控制。

歐洲、中東和非洲的法律規範和採購模式各不相同，有些市場專注於集中評估，而有些市場則依賴國家評估和競標流程。這種多樣性要求制定細緻入微的打入市場策略，以平衡區域申請文件、國家層級的證據和定價彈性。在亞太地區，創新平台的快速普及、生物製造基礎的不斷壯大以及公私醫療保健投資的持續成長，為戰略夥伴關係和區域製造中心的建設創造了沃土。監管時間表、智慧財產權保護和當地臨床實踐模式的差異，使得制定個人化的商業化藍圖勢在必行。在所有地區，跨境貿易措施、當地生產獎勵以及數位醫療的普及應用將繼續影響供應鏈設計和市場准入順序。

公司層面的當務之急，展現了大型製藥網路、專業生物技術和製造合作夥伴如何攜手合作，推動抗病毒藥物的創新和商業化。

企業策略揭示了一個分叉的生態系統：大型綜合製藥公司和靈活的生物技術公司各自追求互補的創新路徑。大型跨國公司利用其深厚的監管專業知識、廣泛的生產網路和全球商業性影響力，推動後期專案並擴大複雜生技藥品的生產規模。同時，專注於具有影響力的科學研究、罕見或孤兒病毒靶點以及顛覆性治療方法的生物技術公司，越來越依賴戰略聯盟、許可協議和里程碑式的合作來加速臨床開發並獲取資金。

受託製造廠商)已成為至關重要的生態系統合作夥伴，它們能夠幫助企業快速擴大規模並實現地域多元化，而無需承擔新建設施的固定成本。此外，專注於遞送技術、診斷和數據主導臨床最佳化的新興參與企業正在重塑企業建立其價值提案的方式。在這種競爭激烈的環境中，成功的企業正在將科學差異化與切實可行的商業化計劃相結合，優先考慮建立持久的生產合作關係，並產生核准後證據以支持其產品在不同醫療保健系統中的應用。

為高階主管提供切實可行的跨職能建議，以增強抗病毒治療價值鏈的韌性、加速藥物取得並最佳化商業化。

產業領導者應採取整合策略，將科學差異化、營運韌性和以市場為導向的證據產生結合。首先，他們應實現關鍵原料和生技藥品成分供應商網路的多元化，同時建立雙源協議和安全庫存政策，以降低供應中斷的風險。同時，他們應投資於靈活且地理分散的生產能力，包括與能夠處理多種治療方式的契約製造製造商合作。

第二，優先發展能夠解決抗藥性問題並拓寬治療前景的平台技術和聯合治療，同時設計以真實世界終點和適應性要素為核心的臨床項目，以支持加速藥物取得。第三，透過最佳化管道以提高依從性、可近性和監控效果，使分銷策略與產品特性相符。例如，將線上藥局計畫和數位依從性工具應用於口服藥物，而注射用生技藥品則透過提供綜合患者支援的專科診所進行分銷。第四，制定能夠體現產品全生命週期價值的定價和合約框架，盡可能納入基於結果的要素，並預估區域支付方的要求。最後，加強跨職能協作，連結研發、監管、生產和商業團隊，確保研發決策反映下游實際情況，並以實證策略支援產品的持續應用。

一項嚴謹的多方法研究途徑，結合了主要相關人員研究、臨床和監管審查、供應鏈分析以及迭代式同行檢驗，確保了研究結果的可操作性。

調查方法採用多種研究方法，結合一手資料和二手資料，以獲得可靠且可重複的研究結果。一手資料包括對臨床研究人員、醫院和專科診所的採購負責人、生產企業高管以及法規事務專家進行結構化訪談。此外，還對臨床試驗註冊庫、同行評審文獻、專利和監管申報文件進行了系統性回顧，以梳理研發軌跡並識別新興科學主題。

為了檢驗我們的研究結果，我們的分析融合了供應鏈圖譜、近期啟動專案的用例，並結合技術資料和相關人員的觀點進行三角驗證。品管包括將訪談結果與已記錄的證據進行交叉檢驗、反覆的專家評審以及針對策略影響的敏感性檢查。最終形成的方法論兼顧了洞察的深度和證據來源的透明度，從而為推進抗病毒療法研發和商業化的決策者提供切實可行的建議。

抗病毒療法的長期成功取決於創新、營運韌性和市場適用性證據的產生。戰略意義已整合

抗病毒療法正處於一個動態的十字路口，技術創新、監管變革和市場力量既帶來了機遇，也帶來了挑戰。科學進步不斷拓展治療套件，而營運和政策的轉變則對供應鏈的韌性和以市場為導向的證據產生提出了更高的要求。能夠將前沿科學與靈活的生產製造、適應性強的臨床策略和本地化的商業化方案相結合的機構將取得最大的成功。

展望未來，最有效的項目將是那些能夠預測抗藥性動態、優先考慮以患者為中心的服務模式，並在生產和分銷網路中建立永續夥伴關係。透過將科學目標與實際執行相結合，相關人員可以加速將實驗室突破轉化為能夠帶來可衡量的臨床和公共衛生效益的治療方法。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 基於mRNA的抗病毒療法針對新出現的病毒株取得了快速進展
  • 將人工智慧應用於抗病毒候選藥物的篩檢和最佳化
  • 在病毒感染的治療中，抗體和小分子聯合治療的應用日益增加。
  • 長效注射型抗病毒藥物的出現，為持續控制慢性病毒性疾病提供了可能。
  • 開發廣譜、宿主特異性抗病毒藥物以防止抗藥性的產生
  • 拓展可吸入奈米顆粒製劑，以改善標靶抗病毒肺部遞送。
  • 在臨床環境中透過病毒基因分型和抗藥性分析進行個人化抗病毒治療
  • 基於 CRISPR-Cas 的基因編輯方法正在進行臨床評估，用於破壞目標病毒基因組。
  • 透過整合電子健康記錄的真實世界證據，監測抗病毒藥物安全性和有效性的趨勢

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章：以疾病類型分類的抗病毒治療市場

  • COVID-19
  • 巨細胞病毒
  • C型肝炎
  • 皰疹
  • HIV
  • 流感
  • 呼吸道融合病毒（RSV）

9. 按藥物類別分類的抗病毒治療市場

  • 融合抑制劑
  • 整合酶抑制劑
  • 干擾素
  • 單株抗體
  • 神經氨酸酶抑制劑
  • NNRTI
  • NRTI
  • 聚合酵素抑制劑
  • 蛋白酶抑制劑

第10章 依給藥途徑分類的抗病毒治療藥物市場

  • 吸入
  • 注射
  • 口服
  • 局部的

第11章 按分銷管道分類的抗病毒治療市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科診所

第12章：按治療類型分類的抗病毒治療市場

  • 預防
  • 治療

第13章：各地區抗病毒治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗病毒治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國抗病毒治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • GlaxoSmithKline plc
    • Bristol-Myers Squibb Company
    • Novartis AG
    • AstraZeneca PLC
Product Code: MRR-037F3DB2591D

The Antiviral Therapeutics Market is projected to grow by USD 157.02 billion at a CAGR of 8.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 82.01 billion
Estimated Year [2025] USD 88.89 billion
Forecast Year [2032] USD 157.02 billion
CAGR (%) 8.45%

Comprehensive orientation to the modern antiviral therapeutics landscape that integrates scientific progress, regulatory realities, and commercial strategy for decision-makers

The antiviral therapeutics landscape stands at the confluence of accelerated scientific discovery, shifting public health expectations, and intensifying commercial competition. Recent years have seen novel modalities and delivery technologies transition from proof-of-concept to clinical reality, catalyzing a more complex but opportunity-rich environment for developers, manufacturers, and payers. Stakeholders must now reconcile therapeutic innovation with cost pressures, supply chain vulnerabilities, and evolving regulatory standards across key global jurisdictions.

As the pathogen spectrum broadens and the emphasis on pandemic preparedness grows, organizations must recalibrate their strategic priorities. Investments in broad-spectrum platforms, host-targeted approaches, and adaptive manufacturing have risen in prominence. At the same time, payers and procurement bodies increasingly scrutinize clinical value and real-world effectiveness, prompting sponsors to design evidence generation strategies that extend beyond pivotal trials. Consequently, leaders who integrate scientific rigor with commercial foresight and operational resilience will shape the next phase of antiviral therapeutics development and delivery.

How converging platform technologies, regulatory innovations, and manufacturing agility are fundamentally altering antiviral drug discovery, development, and delivery

A series of transformative shifts is reshaping how antiviral drugs are discovered, developed, and delivered. Platform technologies that proved adaptable during urgent public health crises are now being repurposed toward a wider range of viral targets, enabling faster lead identification and more agile development pathways. Simultaneously, the maturation of monoclonal antibody engineering and the refinement of host-directed therapies are expanding therapeutic options beyond traditional small-molecule inhibitors.

Digital capabilities and artificial intelligence have accelerated target discovery and optimized candidate selection, while modular and single-use manufacturing solutions are reducing lead times and increasing geographic flexibility. These scientific and operational changes are complemented by regulatory innovation, where expedited pathways and adaptive trial designs are facilitating conditional access for high unmet need indications. Taken together, these shifts underscore a landscape where technological convergence, regulatory agility, and manufacturing adaptability determine commercial success.

Assessing the cumulative operational and strategic consequences of recent United States tariff measures on antiviral supply chains, procurement, and manufacturing decisions

Policy changes and trade measures implemented in 2025 have introduced a new variable into global antiviral supply chains and procurement strategies. Tariff adjustments impacting key raw materials and finished pharmaceuticals have elevated the cost calculus for cross-border sourcing, prompting firms to re-evaluate supplier networks and inventory strategies. In response, many organizations have accelerated efforts to localize production, expand contract manufacturing partnerships, and diversify active pharmaceutical ingredient suppliers to mitigate single-source exposure.

Beyond immediate cost implications, tariffs have influenced long-term strategic choices. Sponsors and manufacturers have revisited site selection decisions for new facilities, factoring in tariff risk alongside labor, talent availability, and regulatory alignment. Procurement organizations in hospitals, retail pharmacies, and specialty clinics have adapted contracting approaches to include greater flexibility around supply guarantees and price escalators. Ultimately, the cumulative impact of trade measures has crystallized the need for resilient, multi-layered supply strategies that preserve continuity of care while maintaining commercial viability.

Strategic segmentation insights tying disease targets, drug classes, administration routes, distribution channels, and therapy objectives to clinical and commercial decision-making

Segmentation-driven analysis reveals differentiated dynamics across therapeutic targets and modalities that should inform portfolio and commercialization choices. Disease-specific considerations vary markedly: responses to acute respiratory viruses demand rapid onset and convenient administration, whereas chronic infections such as hepatitis C and HIV prioritize sustained viral suppression, adherence support, and resistance management. Emerging and re-emerging targets like cytomegalovirus and respiratory syncytial virus require specialized clinical development approaches and often benefit from targeted biologics or prophylactic strategies.

Drug-class distinctions influence development timelines and deployment. Small-molecule polymerase and protease inhibitors typically offer oral dosing advantages and established manufacturing footprints, while monoclonal antibodies and interferons frequently rely on injectable formats and complex biologics production. Fusion and integrase inhibitors, as well as nucleoside and non-nucleoside reverse transcriptase inhibitors, each carry distinct resistance profiles and combination therapy implications. Route of administration further shapes uptake and adherence: oral agents facilitate outpatient treatment and retail pharmacy distribution, injectable formulations often necessitate hospital or specialty clinic involvement, inhalation and topical options serve niche respiratory and localized indications, and delivery mode directly affects reimbursement pathways and patient preference.

Distribution-channel strategies must align with both product attributes and health system capabilities. Hospital pharmacies and specialty clinics play critical roles for parenteral biologics and complex therapeutics that require monitoring, whereas retail and online pharmacies expand access for oral antivirals and prophylactic products. Finally, the therapy objective-prophylaxis versus treatment-dictates clinical trial design, labeling nuances, and post-marketing evidence generation. Prophylactic products often emphasize population-level effectiveness and safety over extended periods, while therapeutic agents prioritize immediate clinical endpoints and resistance surveillance. Integrating these segmentation lenses enables targeted clinical development, tailored market access plans, and optimized commercial deployment.

Regional dynamics and market access imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape development, manufacturing, and commercialization choices

Regional variations create distinct operational and regulatory environments that influence pipeline prioritization and go-to-market tactics. In the Americas, robust clinical trial infrastructure, substantial public and private R&D investment, and a complex reimbursement landscape require evidence packages that demonstrate comparative effectiveness and value over existing standards. Regulatory pathways in this region also accommodate accelerated access mechanisms for high-priority therapies, but stakeholders must navigate pricing scrutiny and payer-driven utilization controls.

Europe, Middle East & Africa present heterogenous regulatory frameworks and procurement models, with some markets emphasizing centralized evaluation and others relying on national assessment and tendering processes. This diversity necessitates nuanced market access strategies that balance regional dossiers with country-level evidence and pricing flexibility. In Asia-Pacific, rapid adoption of innovative platforms, a growing biomanufacturing base, and expanding private and public healthcare investment create fertile ground for strategic partnerships and regional manufacturing hubs. Nevertheless, differences in regulatory timelines, intellectual property enforcement, and local clinical practice patterns require tailored commercialization roadmaps. Across all regions, cross-border trade measures, local production incentives, and digital health adoption will continue to shape supply chain design and market entry sequencing.

Company-level imperatives showing how large pharmaceutical networks, specialized biotechs, and manufacturing partners align to advance antiviral innovation and commercialization

Company strategies reveal a bifurcated ecosystem where large integrated pharmaceutical firms and nimble biotechs pursue complementary pathways to innovation. Established multinationals leverage deep regulatory expertise, broad manufacturing networks, and global commercial reach to advance late-stage programs and scale complex biologics. In parallel, specialized biotechs focus on high-impact science, rare or orphan viral targets, and disruptive modalities, increasingly relying on strategic alliances, licensing arrangements, and milestone-driven collaborations to accelerate clinical development and access capital.

Contract development and manufacturing organizations have become pivotal ecosystem partners, enabling rapid scale-up and geographic diversification without the fixed-cost burden of new facilities. In addition, novel entrants specializing in delivery technologies, diagnostics, and data-driven clinical optimization are reshaping how companies design value propositions. Across the competitive landscape, successful organizations align scientific differentiation with pragmatic commercialization plans, prioritize durable manufacturing relationships, and commit to post-approval evidence generation that supports adoption in diverse healthcare systems.

Practical, cross-functional recommendations for executives to enhance resilience, accelerate access, and optimize commercialization across the antiviral therapeutic value chain

Industry leaders should adopt integrated strategies that combine scientific differentiation with operational resilience and market-focused evidence generation. First, diversify supplier networks for key raw materials and biologics components while establishing dual-source agreements and safety-stock policies to reduce disruption risk. Simultaneously, invest in flexible and geographically distributed manufacturing capacity, including partnerships with contract manufacturers that can pivot across modalities.

Second, prioritize platform technologies and combination approaches that address resistance and broaden the therapeutic window, while designing clinical programs with real-world endpoints and adaptive elements to support accelerated access. Third, align distribution strategies with product profiles by optimizing channels for adherence, access, and monitoring; for instance, pair oral therapies with online pharmacy programs and digital adherence tools, and route injectable biologics through specialty clinics with integrated patient support. Fourth, create pricing and contracting frameworks that reflect value over the product lifecycle, incorporate outcomes-based elements where feasible, and anticipate payer requirements across regions. Finally, strengthen cross-functional collaborations-linking R&D, regulatory, manufacturing, and commercial teams-to ensure that development decisions incorporate downstream deployment realities and that evidence strategies support sustainable uptake.

Rigorous multi-method research approach blending primary stakeholder interviews, clinical and regulatory review, supply chain mapping, and iterative expert validation to ensure actionable insights

The research approach combined multi-modal primary and secondary methods to ensure robust, reproducible insights. Primary engagements included structured interviews with clinical investigators, procurement leaders in hospitals and specialty clinics, manufacturing executives, and regulatory affairs specialists. These qualitative inputs were complemented by systematic reviews of clinical trial registries, peer-reviewed literature, patents, and regulatory filings to map development trajectories and identify emergent scientific themes.

To validate findings, the analysis incorporated supply chain mapping exercises, case studies of recent program launches, and triangulation of technical data with stakeholder perspectives. Quality controls included cross-validation between interview outputs and documentary evidence, iterative expert review cycles, and sensitivity checks on strategic implications. The result is a methodology that balances depth of insight with transparency of evidence sources and that supports pragmatic recommendations for decision-makers navigating antiviral therapeutic development and commercialization.

Synthesis of strategic implications where innovation, operational resilience, and market-aligned evidence generation determine long-term success in antiviral therapeutics

Antiviral therapeutics occupy a dynamic juncture where technological innovation, regulatory evolution, and market forces converge to create both opportunity and complexity. Scientific advances are expanding the therapeutic toolkit, while operational and policy shifts demand greater supply chain resilience and market-focused evidence generation. Success will favor organizations that can integrate cutting-edge science with flexible manufacturing, adaptive clinical strategies, and regionally tailored commercialization plans.

Looking ahead, the most effective programs will be those that anticipate resistance dynamics, prioritize patient-centric delivery models, and establish durable partnerships across manufacturing and distribution networks. By aligning scientific ambition with pragmatic execution, stakeholders can accelerate the translation of laboratory breakthroughs into therapies that deliver measurable clinical and public health benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid advancement of mRNA-based antiviral therapeutics targeting emerging viral strains
  • 5.2. Integration of artificial intelligence in antiviral drug candidate screening and optimization
  • 5.3. Growing adoption of combination antibody and small molecule therapies for viral infection management
  • 5.4. Emergence of long acting injectable antivirals for sustained suppression of chronic viral diseases
  • 5.5. Development of broad-spectrum host-directed antivirals to reduce resistance development
  • 5.6. Expansion of inhalable nanoparticle formulation to improve targeted antiviral lung delivery
  • 5.7. Personalized antiviral regimens guided by viral genotyping and resistance profiling in clinics
  • 5.8. CRISPR-Cas based gene editing approaches under clinical evaluation for targeted viral genome disruption
  • 5.9. Real world evidence integration from electronic health records to monitor antiviral safety and efficacy trends

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Therapeutics Market, by Disease Type

  • 8.1. Covid-19
  • 8.2. Cytomegalovirus
  • 8.3. Hepatitis C
  • 8.4. Herpes
  • 8.5. Hiv
  • 8.6. Influenza
  • 8.7. Respiratory Syncytial Virus

9. Antiviral Therapeutics Market, by Drug Class

  • 9.1. Fusion Inhibitors
  • 9.2. Integrase Inhibitors
  • 9.3. Interferons
  • 9.4. Monoclonal Antibodies
  • 9.5. Neuraminidase Inhibitors
  • 9.6. Nnrtis
  • 9.7. Nrtis
  • 9.8. Polymerase Inhibitors
  • 9.9. Protease Inhibitors

10. Antiviral Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical

11. Antiviral Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Specialty Clinics

12. Antiviral Therapeutics Market, by Therapy Type

  • 12.1. Prophylaxis
  • 12.2. Treatment

13. Antiviral Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiviral Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. AbbVie Inc.
    • 16.3.3. F. Hoffmann-La Roche Ltd.
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. Pfizer Inc.
    • 16.3.6. Johnson & Johnson
    • 16.3.7. GlaxoSmithKline plc
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. Novartis AG
    • 16.3.10. AstraZeneca PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THE